Curanex Pharmaceuticals Inc Common Stock (CURX)

FairStock Score: 10/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first for a business with durable earnings and a margin of safety. Curanex fails that test today. It is a developmental-stage botanical drug company with six employees, no revenue in FY2025 (the year ended 2025-12-31) or FY2024 (the year ended 2024-12-31), and a net loss of $4.2 million in FY2025 versus $361,506 in FY2024. The deterioration has accelerated: in fiscal Q2 2026 (the quarter ended 2026-06-30), the net loss was $3.3 million, or $0.12 per diluted share, after a $3.2 million loss in fiscal Q1 2026 (the quarter ended 2026-03-31). Those two quarters alone lost about $6.5 million, more than the full FY2025 loss. Free cash flow is negative $12.1 million on a trailing basis, a negative 7.9% FCF yield on the $153.1 million market cap. The balance sheet shows low leverage, with a D/E of 0.06 and an Altman Z-Score of 318.81 per FairStock's calculation, but that is cold comfort when there is no revenue and cash is being consumed. FairStock's calculations at the 2026-10-13 close show P/B 1.44, P/E -0.66, ROE -411.08%, ROCE -225.06%, Piotroski F-Score 1/9, and FairStock Score 10/100. The Lynch category is none because only two years of filed results exist; I need at least three to judge a track record. There is no evidence of a moat: no revenue, no approved product, six employees, and no three-year history. The 52-week range of $0.18 to $6.80 tells me the market is pricing a lottery ticket, not a proven compounding machine. Until Phyto-N shows clinical progress and a credible path to revenue without crippling dilution, this is speculation, not value.

In plain English: Curanex Pharmaceuticals is a tiny developmental drug company with six employees. It is trying to develop a botanical drug called Phyto-N for inflammatory conditions. It has no reported revenue, keeps losing money, and at $4.88 its $153 million market value looks high compared with those losses.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer